Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Invested Capital (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Invested Capital for 12 consecutive years, with 0.09% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Invested Capital rose 19.0% to 0.09% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.09%, a 19.0% increase, with the full-year FY2020 number at 1.16%, down 70.0% from a year prior.
  • Return on Invested Capital was 0.09% for Q3 2025 at Theravance Biopharma, down from 0.06% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.93% in Q1 2021 to a low of 0.35% in Q1 2025.
  • A 5-year average of 0.12% and a median of 0.19% in 2023 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: tumbled -93bps in 2023, then grew 19bps in 2025.
  • Theravance Biopharma's Return on Invested Capital stood at 0.89% in 2021, then plummeted by -122bps to 0.2% in 2022, then dropped by -25bps to 0.25% in 2023, then crashed by -33bps to 0.33% in 2024, then soared by 73bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Return on Invested Capital are 0.09% (Q3 2025), 0.06% (Q2 2025), and 0.35% (Q1 2025).